Effects of 12weeks high dose vitamin D3 treatment on insulin sensitivity, beta cell function, and metabolic markers in patients with type 2 diabetes and vitamin D insufficiency – a double-blind, randomized, placebo-controlled trial

Kampmann, Ulla; Mosekilde, Leif; Juhl, Claus Bogh; Møller, Niels; Christensen, Britt; Rejnmark, Lars; Wamberg, Louise; Ørskov, L.

doi:10.1016/j.metabol.2014.06.008

Cited by 123 publications

(89 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The quality assessment of the studies resulted in 14 out of 23 studies having a good quality (Appendix 1, see section on Appendix given at the end of this article) (12,19,20,21,22,23,24,25,26,27,28,29,30,31). The main characteristics and main outcomes of the included studies are given in Table 1.…”

Section: Description Of the Studiesmentioning

confidence: 99%

“…The main characteristics and main outcomes of the included studies are given in Table 1. All studies had a randomized controlled trial design, of which 18 studies used a placebo for control (12,19,20,22,23,24,25,27,29,30,31,32,33,34,35,36,37,38), three studies compared vitamin D fortified yoghurt versus plain yoghurt (21,28,39), one study used oral calcium supplementation for control (26), and one study used vitamin C supplementation for control (40). Apart from two studies, which solely included post-menopausal women (21,33), all studies included both men and women.…”

Section: Description Of the Studiesmentioning

confidence: 99%

“…Of the 23 studies that were included in the systematic review, 13 reported fasting glucose as primary or secondary outcome measure (19,20,21,22,23,24,26,27,28,32,35,36,39). Three studies reported a significant reduction in fasting glucose level after vitamin D supplementation (21,28,39).…”

Section: The Effect On Fasting Glucosementioning

confidence: 99%

“…Thirteen studies reported data on insulin resistance, of which twelve studies used the HOMA-IR to quantify insulin resistance (19,20,21,22,24,25,26,29,30,35,36,39), and one study measured insulin resistance through hyperinsulinaemic-euglycaemic clamp method (23). Two studies observed a significant reduction in insulin resistance after vitamin D supplementation (21,39), and one study found a negative effect of vitamin D supplementation on insulin resistance compared with placebo (35).…”

Section: The Effect On Insulin Resistancementioning

confidence: 99%

See 3 more Smart Citations

MANAGEMENT OF ENDOCRINE DISEASE: The effect of vitamin D supplementation on glycaemic control in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

Krul-Poel

Wee

Lips

et al. 2017

European Journal of Endocrinology

101

View full text Add to dashboard Cite

Objective: Epidemiologic studies suggest that vitamin D status plays a role in glycaemic control in patients with type 2 diabetes. However, intervention studies yielded inconsistent results. The aim of this study is to systematically review the effect of vitamin D supplementation on glycaemic control in patients with type 2 diabetes. Methods: Systematic review and meta-analysis. We searched Medline, Embase and the Cochrane Library for RCTs examining the effect of vitamin D supplementation on glycaemic control in patients with type 2 diabetes. A random-effects model meta-analysis was performed to obtain a summarized outcome of vitamin D supplementation on HbA 1c , fasting glucose and homeostasis model assessment -insulin resistance (HOMA-IR). Results: Twenty-three RCTs were included in this systematic review representing a total of 1797 patients with type 2 diabetes. Mean (± s.d.) change in serum 25-hydroxyvitamin D varied from 1.8 ± 10.2 nmol/L to 80.1 ± 54.0 nmol/L. Nineteen studies included HbA 1c as outcome variable. Combining these studies no significant effect in change of HbA 1c was seen after vitamin D intervention compared with placebo. A significant effect of vitamin D supplementation was seen on fasting glucose in a subgroup of studies (n = 4) with a mean baseline HbA 1c ≥ 8% (64 mmol/mol) (standardized difference in means: 0.36; 95% CI: 0.12-0.61, P = 0.003). Conclusions: Current evidence of RCTs does not support short-term vitamin D supplementation in a heterogeneous population with type 2 diabetes. However, in patients with poorly controlled diabetes, a favourable effect of vitamin D is seen on fasting glucose.

show abstract

Section: Description Of the Studiesmentioning

confidence: 99%

Section: Description Of the Studiesmentioning

confidence: 99%

Section: The Effect On Fasting Glucosementioning

confidence: 99%

Section: The Effect On Insulin Resistancementioning

confidence: 99%

See 2 more Smart Citations

MANAGEMENT OF ENDOCRINE DISEASE: The effect of vitamin D supplementation on glycaemic control in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

Krul-Poel

Wee

Lips

et al. 2017

European Journal of Endocrinology

101

View full text Add to dashboard Cite

show abstract

“…8,9 Molecular effects of vitamin D receptor activation, such as suppression of the renin-angiotensin-aldosterone system (RAAS), nephroprotective actions, or improvements in endothelial/vascular function, suggest antihypertensive properties of vitamin D. 6,9 Several randomized controlled trials (RCTs) on vitamin D supplementation and BP have already been performed but have shown mixed results with most studies reporting no significant effect and only some showing that vitamin D lowers BP. [9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28] In a metaanalysis of RCTs, vitamin D supplementation resulted in a nonsignificant reduction in systolic and diastolic BP. 10 A significant decrease in diastolic BP was observed among RCTs including participants with pre-existing cardiometabolic disease.…”

mentioning

confidence: 99%

Effects of Vitamin D on Blood Pressure and Cardiovascular Risk Factors

et al. 2015

View full text Add to dashboard Cite

A part from skeletal diseases, vitamin D deficiency is considered a risk factor for cardiovascular events and mortality. [1][2][3][4][5][6] Nevertheless, it remains unclear whether low 25-hydroxyvitamin D (25[OH]D) concentrations are a significant causal risk factor or are simply related to adverse outcomes because of reverse causation and confounding factors, such as obesity, reduced mobility with low sunlight exposure, poor nutrition, or inflammation. [1][2][3][4][5][6] Because high blood pressure (BP) has emerged as the leading risk factor for the global disease burden, it is important to evaluate whether vitamin D has a beneficial effect on lowering BP to clarify the potential role of vitamin D for public health. 7 Large observational studies and meta-analyses have shown that low 25(OH)D concentrations are a significant risk marker for arterial hypertension. 8,9 Molecular effects of vitamin D receptor activation, such as suppression of the renin-angiotensin-aldosterone system (RAAS), nephroprotective actions, or improvements in endothelial/vascular function, suggest Abstract-Vitamin D deficiency is a risk factor for arterial hypertension, but randomized controlled trials showed mixed effects of vitamin D supplementation on blood pressure (BP). We aimed to evaluate whether vitamin D supplementation affects 24-hour systolic ambulatory BP monitoring values and cardiovascular risk factors. The Styrian Vitamin D Hypertension Trial is a single-center, double-blind, placebo-controlled study conducted from June 2011 to August 2014 at the endocrine outpatient clinic of the Medical University of Graz, Austria. We enrolled 200 study participants with arterial hypertension and 25-hydroxyvitamin D levels below 30 ng/mL. Study participants were randomized to receive either 2800 IU of vitamin D3 per day as oily drops (n=100) or placebo (n=100) for 8 weeks. Primary outcome measure was 24-hour systolic BP. Secondary outcome measures were 24-hour diastolic BP, N-terminal-pro-B-type natriuretic peptide, QTc interval, renin, aldosterone, 24-hour urinary albumin excretion, homeostasis model assessment-insulin resistance, triglycerides, highdensity lipoprotein cholesterol, and pulse wave velocity. Methods Study DesignThe Styrian Vitamin D Hypertension Trial was sponsored by the Medical University of Graz, Austria, and is a single-center, double-blind, placebo-controlled, parallel-group study conducted at the Medical University of Graz, Austria. The publication of this trial adheres to the Consolidated Standards of Reporting Trials (CONSORT) 2010 statement. 29 The trial was initially registered at http://www.clinicaltrialsregister.eu (EudraCT number, 2009-018125-70) and was additionally registered at clinicaltrials.gov (ClinicalTrials.gov Identifier NCT02136771). ParticipantsEligible study participants were adults aged ≥18 years with arterial hypertension and a 25(OH)D serum concentration below 30 ng/mL (multiply by 2.496 to convert ng/mL to nmol/L). Arterial hypertension was classified in patients with an office BP of systol...

show abstract

Vitamin D ratio and glycaemic control in individuals with type 2 diabetes mellitus: A systematic review

Santos

Brandão-Lima

Tête

et al. 2017

Diabetes Metabolism Res

View full text Add to dashboard Cite

Several studies have suggested a favorable role for vitamin D in glycaemic metabolism and its potential as adjuvant treatment of type 2 diabetes mellitus. This review discusses the role of vitamin D in the glycaemic control of individuals with type 2 diabetes mellitus and evaluates the effect of vitamin D supplementation on glycaemic markers in this population. Literature searches were performed in the BIREME, LILACS, and PubMed databases using the Medical Subject Headings and words related to vitamin D, type 2 diabetes mellitus, and glycaemic control. Interventional and observational studies were considered eligible. The evaluation of the included studies was independently performed by 2 evaluators at all stages of selection, data extraction, and bias risk assessment. The primary outcome was the relationship between vitamin D levels and glucose metabolism markers in type 2 diabetes mellitus individuals. The secondary outcome was the effect of vitamin D supplementation on the glycaemic control markers in individuals with type 2 diabetes mellitus. The inverse relationship between vitamin D and variables of glucose metabolism was verified. Interventional studies revealed that vitamin D supplementation did not alter glycaemic control markers in most studies. Few studies have shown positive effects with a significant reduction in the percentage of glycated haemoglobin, insulin, and glucose concentrations, and changes in homeostatic model assessment-insulin resistance and beta cell, and quantitative insulin sensitivity check index. Therefore, despite the association of vitamin D with glucose metabolism, there is insufficient evidence of the beneficial effects of its supplementation on the metabolic control of type 2 diabetes mellitus.

show abstract

Effects of 12weeks high dose vitamin D3 treatment on insulin sensitivity, beta cell function, and metabolic markers in patients with type 2 diabetes and vitamin D insufficiency – a double-blind, randomized, placebo-controlled trial

Cited by 123 publications

References 43 publications

MANAGEMENT OF ENDOCRINE DISEASE: The effect of vitamin D supplementation on glycaemic control in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

MANAGEMENT OF ENDOCRINE DISEASE: The effect of vitamin D supplementation on glycaemic control in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

Effects of Vitamin D on Blood Pressure and Cardiovascular Risk Factors

Vitamin D ratio and glycaemic control in individuals with type 2 diabetes mellitus: A systematic review

Contact Info

Product

Resources

About